In Good Company with Nicolai Tangen Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk
Jul 24, 2024
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, dives into the pressing issue of obesity as a complex health crisis. He shares insights on the company's innovative GLP-1 medication, addressing the major challenges of accessibility in Europe and the U.S. Jørgensen emphasizes the significance of purpose in the pharmaceutical industry and reflects on grounded leadership principles. The discussion also touches on navigating cultural differences in global teams and the value of non-linear career paths for fostering a sustainable work-life balance.
AI Snips
Chapters
Transcript
Episode notes
Obesity as a Disease
- Obesity is increasingly recognized as a disease influenced by genetics and physiology, not just lifestyle.
- This recognition is driving demand for effective treatments, changing the market.
Novo Nordisk's Obesity Drug
- Novo Nordisk's GLP-1 drug, initially for diabetes, was found to be effective for weight loss.
- The second-generation GLP-1 drug showed significant weight loss, changing the obesity market.
US vs. Europe Pharma Markets
- The US market is open to innovation due to its private healthcare system, leading to faster adoption of new drugs.
- Europe's pharmaceutical market is less attractive due to longer approval times and complex reimbursement processes.